We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RZLT market cap is 287.4M. The company's latest EPS is USD -1.1815 and P/E is -4.20.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.91M | -15.19M | -16.21M | -23.1M | -16.94M |
| Net Income | -14.52M | -13.91M | -17.05M | -22.98M | -15.38M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -20.52M | -22.89M | -41.84M | -55.99M | -70.42M |
| Net Income | -20.33M | -20.9M | -41.06M | -51.79M | -68.46M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 113M | 102.15M | 87.74M | 132.74M | 123.41M |
| Total Liabilities | 9.44M | 10.42M | 16.88M | 11.73M | 9.97M |
| Total Equity | 103.56M | 91.73M | 70.86M | 121M | 113.44M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.97M | 42.61M | 152.42M | 123.72M | 132.74M |
| Total Liabilities | 3.6M | 16.51M | 2.95M | 7.55M | 11.73M |
| Total Equity | 7.37M | 26.1M | 149.47M | 116.17M | 121M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.59M | -23.61M | -38.85M | -57.37M | -16.01M |
| Investing | 2.61M | 20.37M | 29.04M | 48.7M | -49.41M |
| Financing | N/A | -293k | -296k | 63.03M | 5.5M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -24.17M | -20.44M | -39.62M | -44.48M | -57.37M |
| Investing | N/A | N/A | N/A | -101.46M | 48.7M |
| Financing | 22.55M | 51.53M | 148.98M | 11.57M | 63.03M |
| Market Cap | 287.4M |
| Price to Earnings Ratio | -4.20 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 4.08 |
| Price to Book Ratio | 2.38 |
| Dividend Yield | - |
| Shares Outstanding | 57.94M |
| Average Volume (1 week) | 296.53k |
| Average Volume (1 Month) | 387.34k |
| 52 Week Change | 451.11% |
| 52 Week High | 6.1856 |
| 52 Week Low | 0.90 |
| Spread (Intraday) | 0.11 (2.22%) |
| Company Name | Rezolute Inc |
| Address |
187 e warm springs road las vegas, nevada 89119 |
| Website | https://www.rezolutebio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
